ProKidney Corp. (PROK)

NASDAQ: PROK · IEX Real-Time Price · USD
7.62
-0.14 (-1.80%)
Aug 16, 2022 2:43 PM EDT - Market open
-1.80%
Market Cap 468.94M
Revenue (ttm) n/a
Net Income (ttm) -144.76M
Shares Out 61.54M
EPS (ttm) -0.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,883
Open 7.75
Previous Close 7.76
Day's Range 7.27 - 7.75
52-Week Range 6.19 - 11.98
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About PROK

Social Capital Suvretta Holdings Corp. III does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on searching for a target business operating in the biotechnology industry and within the organ space sub-sector. Social Capital Suvretta Holdings Corp. III was incorporated in 2021 and is based in Henderson, Nevada. [Read more...]

Industry Shell Companies
Founded 2015
Employees 4
Stock Exchange NASDAQ
Ticker Symbol PROK
Full Company Profile

Financial Performance

Financial Statements

News

ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update

Completed business combination with Social Capital Suvretta Holdings, III Completed business combination with Social Capital Suvretta Holdings, III

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney

ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Extensive Nephrology Medical Affairs Leadership and Clinical Practice Expertise Brought to ProKidney Extensive Nephrology Medical Affairs Leadership and Clinical Practice Expertise Brought to ProKidney

Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combinat...

WINSTON-SALEM, N,C. and PALO ALTO, Calif., July 12, 2022 (GLOBE NEWSWIRE) --  ProKidney LP (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on CKD, and Social Capital S...

Other symbols: DNAA

Social Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of Shareholders

PALO ALTO, Calif.--(BUSINESS WIRE)--Social Capital Suvretta Holdings Corp. III (“SCS”) today announced that it will reconvene the Extraordinary General Meeting of its shareholders to vote on the Busines...

ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic ...

WINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the p...

ProKidney Announces Manufacturing Efficiency Initiatives and Supply Chain Streamlining Expected to Reduce REACT™ Manu...

Company anticipates that costs for REACT™ could decrease by up to 50% compared to the cost of manufacturing for its Phase 2 clinical trial Company anticipates that costs for REACT™ could decrease by up ...

Observed Safety Profile Supports Bilateral Dosing of ProKidney's REACT™ – 007 Update

Potential for Amplified Therapeutic Effect of REACT™ with Bilateral Kidney Injections

ProKidney to present at upcoming investor conferences

WINSTON-SALEM, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the pr...

ProKidney highlights key registrational program elements supporting advancement of REACT®

WINSTON-SALEM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the pr...

ProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical Officer

WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and prev...

ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022

WINSTON-SALEM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney) is a leading Phase 3 clinical-stage cellular therapeutics company with Regenerative Medicine Advanced Therapy (RMAT) Desi...

ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®

Two Phase 3 controlled trials with substantially similar design to enroll 1,200 subjects with diabetic CKD Two Phase 3 controlled trials with substantially similar design to enroll 1,200 subjects with d...

ProKidney Appoints Todd C. Girolamo as General Counsel

WINSTON-SALEM, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevent...

DNAC Stock: 11 Things to Know Ahead of the ProKidney SPAC Merger

Palihapitiya's SPAC with ProKidney is expected to close during Q3 of this year. Here's what you need to know about the biotech company.

ProKidney to Present REACT® at 4th Annual CKD Summit

WINSTON-SALEM, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevent...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Social Capital Suvretta Holdings Corp. III Merger

Wilmington, Delaware--(Newsfile Corp. - February 4, 2022) - Rigrodsky Law, P.A. announces that it is investigating Social Capital Suvretta Holdings Corp. III ("Suvretta III") (NASDAQ: DNAC) regarding po...

ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous C...

WINSTON SALEM, N.C., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”), today announced the p...

7 Worst SPACs for Smart Investors to Skip in 2022

SPACs may make a comeback in 2022. But some of them won't ever recover.

ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal

ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital Suvretta Holdings Corp III  (NASDAQ...

DNAC Stock Alert: Chamath Palihapitiya's SPAC Preps for ProKidney Merger

Investors are excited to hear that dealmaker Chamath Palihapitiya is proceeding with a new SPAC deal involving ProKidney. The post DNAC Stock Alert: Chamath Palihapitiya's SPAC Preps for ProKidney Merge...

ProKidney set to go public after SPAC merger that values combined company at $2.6 billion

ProKidney LP, a cellular therapeutics company focused on kidney disease, announced an agreement to merge with special purpose acquisition company (SPAC) Social Capital Suvretta Holdings Corp. III DNAC, ...

Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combinatio...

WINSTON-SALEM, N.C. & PALO ALTO, Calif.--(BUSINESS WIRE)--ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”), has entered into a...

2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?

The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market closed on Friday and both in...

Other symbols: DNAA